c-LEcta expands product range to include additional enzyme NuCLEANase®

c-LEcta, a global biotechnology company with technology leadership in enzyme engineering and bioprocess development, is launching a newly developed...

read more


OFB Projektentwicklung realises biotechnology campus in Leipzig and thus creates new headquarters for c-LEcta

Leipzig, 14.10.2021
OFB is developing a biotechnology campus in Leipzig by the fourth quarter of 2024. The first section with around 10,425 m² of...

read more


Successful development of a screening method in Bacillus

c-LEcta expands its ENESYZ® technology platform, using enzyme engineering to optimize more enzymes with better results.

read more


Drug Master File for the use of the enzyme DENARASE® in the pharmaceutical industry accepted by the US FDA

Successful submission of a Master File to the U.S. Food and Drug Administration for the product DENARASE®, with assigned reference number MF 27708


read more


c-LEcta exceeds EUR 10 million in revenue with significantly higher EBITDA

c-LEcta managed to grow strongly once again in 2020. Despite a generally challenging economic environment, revenue in the past fiscal year rose by 14%...

read more


European dossiers submitted for approval of new enzymes in the food industry

c-LEcta has submitted dossiers for two newly developed enzymes in the food sector. The evaluation by EFSA (European Food Safety Agency) and the EU...

read more


Plastic waste from c-LEcta laboratories gets second chance

c-LEcta is donating their plastic waste from laboratory to the Kunststofferei, Leipzig - the local department of global Precious Plastic initiative.

read more


EXCiPACT certification for c-LEcta’s high production standards

The certificate confirms compliance with particularly high quality standards in production and distribution. For customers from the pharmaceutical...

read more